The use of SGLT2-is is currently under research for beneficial effects in HF patients and the subgroup using SGLT2-is and receiving finerenone in FIGARO-DKD demonstrated greater beneficial effects on the composite outcome of cardiovascular death and hospitalization for HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.